Randomized, Crossover Safety and Pharmacokinetics Study of PT010

Inclusion Criteria: * Informed Consent Form (ICF) prior to any study related procedures * Male and female subjects first generation Japanese subjects 18 to 55 years, inclusive * Body weight ≥50 kg (110 lbs) at the Screening Visit and body mass index between 18.5 and 32 kg/m2, inclusive * Good general health * Medically acceptable contraception for women of child-bearing potential and males with female partners of childbearing potential * Clinical labs within normal ranges or determined to be not clinically significant by the Investigator Exclusion Criteria: * Pregnancy, nursing female subjects, or subjects trying to conceive * Clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study * History of ECG abnormalities * Cancer not in complete remission for at least 5 years * Clinically significant, symptomatic prostatic hypertrophy * Male subjects with a trans-urethral resection of the prostate or full resection of the prostate within 6 months prior to Screening * Clinically significant bladder neck obstruction or urinary retention * Inadequately treated glaucoma * History of an allergic reaction or hypersensitivity to any drug or to any component of the formulations used in this study * Subjects with pre-existing anemia and/or iron deficiency